Skip to main content

Advertisement

Log in

Gemcitabine for palliative treatment in metastatic breast cancer

  • REVIEW
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Gemcitabine is one of the recently developed drugs with a high efficacy in various malignant tumours and a mild toxicity profile. As monochemotherapy in metastatic breast cancer, gemcitabine yielded response rates up to 46% as first- and second-line treatment. Neutropenia is the clinically most relevant unwanted effect. Haematological and nonhaematological toxicities are mild, making dose reductions, delays of treatment or withdrawal from treatment very rare. The first phase I and phase II studies of gemcitabine in combination with anthracyclines have shown a good toxicity profile and promising remission rates. Phase I experiences with long-time infusion schedules reveal good feasibility and high patient acceptance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received: 5 March 1998 / Accepted: 15 July 1998

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lüftner, D., Flath, B., Akrivakis, C. et al. Gemcitabine for palliative treatment in metastatic breast cancer. J Cancer Res Clin Oncol 124, 527–531 (1998). https://doi.org/10.1007/s004320050210

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s004320050210

Navigation